Durability of a Vesicular Stomatitis Virus-Based Marburg Virus Vaccine in Nonhuman Primates
暂无分享,去创建一个
H. Feldmann | L. Hensley | C. Mire | T. Geisbert | J. Geisbert | Krystle N. Agans | Elizabeth A. Fritz | B. Satterfield | Krista M. Versteeg | Benjamin A. Satterfield
[1] A. Schmaljohn. Protective antiviral antibodies that lack neutralizing activity: precedents and evolution of concepts. , 2013, Current HIV research.
[2] D. Schmid,et al. Varicella immunity in vaccinated healthcare workers. , 2013, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[3] M. Katze,et al. Antibodies are necessary for rVSV/ZEBOV-GP–mediated protection against lethal Ebola virus challenge in nonhuman primates , 2013, Proceedings of the National Academy of Sciences.
[4] A. Mbonye,et al. Repeated outbreaks of viral hemorrhagic fevers in Uganda. , 2013, African health sciences.
[5] K. Mansfield,et al. Recombinant Vesicular Stomatitis Virus Vaccine Vectors Expressing Filovirus Glycoproteins Lack Neurovirulence in Nonhuman Primates , 2012, PLoS neglected tropical diseases.
[6] L. Rombo,et al. Immunogenicity of delayed TBE-vaccine booster. , 2012, Vaccine.
[7] H. Feldmann,et al. Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections. , 2011, The Journal of infectious diseases.
[8] H. Artsob,et al. Management of accidental exposure to Ebola virus in the biosafety level 4 laboratory, Hamburg, Germany. , 2011, The Journal of infectious diseases.
[9] M. Wallace,et al. Long-term durability of immune responses after hepatitis A vaccination among HIV-infected adults. , 2011, The Journal of infectious diseases.
[10] H. Feldmann,et al. Progress in filovirus vaccine development: evaluating the potential for clinical use , 2011, Expert review of vaccines.
[11] H. Feldmann,et al. Prospects for immunisation against Marburg and Ebola viruses , 2010, Reviews in medical virology.
[12] Joshua C. Johnson,et al. Postexposure Treatment of Marburg Virus Infection , 2010, Emerging infectious diseases.
[13] S. Nichol,et al. Ebola and marburg hemorrhagic fever. , 2010, Clinics in laboratory medicine.
[14] X. Qiu,et al. Mucosal Immunization of Cynomolgus Macaques with the VSVΔG/ZEBOVGP Vaccine Stimulates Strong Ebola GP-Specific Immune Responses , 2009, PloS one.
[15] N. Sullivan,et al. Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule , 2009, Nature Reviews Microbiology.
[16] Heinz Feldmann,et al. Single-Injection Vaccine Protects Nonhuman Primates against Infection with Marburg Virus and Three Species of Ebola Virus , 2009, Journal of Virology.
[17] Steven J M Jones,et al. Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. , 2008, Vaccine.
[18] Steven J M Jones,et al. Vesicular Stomatitis Virus-Based Ebola Vaccine Is Well-Tolerated and Protects Immunocompromised Nonhuman Primates , 2008, PLoS pathogens.
[19] W. Kalina,et al. Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. , 2007, The Journal of infectious diseases.
[20] P. Formenty,et al. Marburg Virus Angola Infection of Rhesus Macaques: Pathogenesis and Treatment with Recombinant Nematode Anticoagulant Protein c2 , 2007, The Journal of infectious diseases.
[21] D. Kaslow. Biological Feasibility of Developing Prophylactic Vaccines for Viral Pathogens: Incubation Period as a Critical Parameter , 2007, Human vaccines.
[22] H. Feldmann,et al. Cross-Protection against Marburg Virus Strains by Using a Live, Attenuated Recombinant Vaccine , 2006, Journal of Virology.
[23] J. A. Comer,et al. Marburgvirus Genomics and Association with a Large Hemorrhagic Fever Outbreak in Angola , 2006, Journal of Virology.
[24] L. Fernando,et al. Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment , 2006, The Lancet.
[25] Heinz Feldmann,et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses , 2005, Nature Medicine.
[26] H. Feldmann,et al. Properties of Replication-Competent Vesicular Stomatitis Virus Vectors Expressing Glycoproteins of Filoviruses and Arenaviruses , 2004, Journal of Virology.
[27] C. Hanlon,et al. Rabies DNA vaccination of non-human primates: post-exposure studies using gene gun methodology that accelerates induction of neutralizing antibody and enhances neutralizing antibody titers. , 2002, Vaccine.
[28] B. Ward,et al. Development and durability of measles antigen-specific lymphoproliferative response after MMR vaccination. , 2000, Vaccine.
[29] M. Whitt,et al. Recombinant vesicular stomatitis viruses from DNA. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[30] K. Johnson,et al. MARBURG-VIRUS DISEASE IN KENYA , 1982, The Lancet.
[31] S. Halstead,et al. Rubella antibody persistence after immunization. , 1982, JAMA.
[32] R. Salt,et al. PERCUTANEOUS LUNG BIOPSY , 1976, The Lancet.
[33] M. Hilleman,et al. Jeryl Lynn strain live attenuated mumps virus vaccine. Durability of immunity following administration. , 1968, JAMA.